NervGen Announces First Participant Dosed in RESTORE, a Phase 3 Registrational Study Evaluating NVG-291 in Chronic Spinal Cord Injury
NervGen dosed the first participant in RESTORE, a Phase 3 registrational study of NVG-291 in chronic cervical motor-incomplete spinal cord injury. The trial plans to enroll roughly 150 participants across the US and Canada, with enrollment completion targeted for the second half of 2027 and topline data expected in the first half of 2028.
Key figures
- Drug Name
- NVG-291
- Phase Of Trial
- Phase 3
- Trial name
- RESTORE
- Topline data
- first half of 2028
- Primary endpoint
- hand function measured by GRASSP Quantitative Prehension
- Planned enrollment
- approximately 150 participants
- Enrollment completion
- second half of 2027
- Regulatory designations
- ["FDA Fast Track","EMA Orphan Drug"]
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.